ViaLase Laser Receives CE Mark Approval to Treat Glaucoma

ViaLase announced that it has received CE Mark approval in the European Union for the ViaLase laser for the treatment of adult patients with primary open-angle glaucoma.

According to the company, the ViaLase laser combines the precision of a femtosecond laser and the accuracy of micron-level image guidance to deliver a noninvasive glaucoma treatment called FLigHT—femtosecond laser, image-guided, high-precision trabeculotomy.

The ViaLase technology provides patients with an option of a non-pharmacologic, incision-free procedure to treat glaucoma, stated the company.

The company also announced that in preparation for commercialization in select European markets later this year, it has established strategic distribution partnerships with Teleon Surgical (Germany and Austria) and Global Surgical Service (Spain and Portugal).

The ViaLase laser is not approved for use in the United States, advised the company.